An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome

Study Summary

Stoke Therapeutics is evaluating the long-term safety \& tolerability of repeated doses of zorevunersen (STK-001) in patients with Dravet syndrome who previously participated in studies of zorevunersen. Change in seizure frequency and overall clinical status, and quality of life will be measured as secondary endpoints in this open-label study.

Conditions

Dravet Syndrome

Interventions / Drugs

zorevunersen (STK-001)

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment60 participants

Primary Completion—

Lead SponsorStoke Therapeutics, Inc

Data Retrieved2026-04-11 04:28:23.454433+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.